All In Biotech

NDA 208854 · Bdsi

Symproic

Naldemedine Tosylate · Oral

Novel

Last checked: Nov 20, 2026Latest source record: Jul 15, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Mar 23, 2017

Approved uses

1

Original approval plus efficacy supplements

Registered trials

10

4 Phase 3, 3 recruiting

FAERS reports

1,662

1,228 serious, 465 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 25, 2025.

SYMPROIC is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. SYMPROIC is an opioid antagonist indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation ( 1 )

Mechanism: Naldemedine is an opioid antagonist with binding affinities for mu-, delta-, and kappa-opioid receptors. Naldemedine functions as a peripherally-acting mu-opioid receptor antagonist in tissues such as the gastrointestinal tract, thereby decreasing the constipating effects of opioids. Naldemedine is a derivative of naltrexone to which a side chain has been added that increases the molecular weight and the polar surface area, thereby reducing its ability to cross the blood-brain barrier (BBB). Naldemedine is also a substrate of the P-glycoprotein (P-gp) efflux transporter. Based on these...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 23, 2017 Original approval · Type 1 - New Molecular Entity NovelLetterLabelReview
1 products under this application
  • SYMPROIC · NALDEMEDINE TOSYLATE EQ 0.2MG BASE · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Naldemedine" as an intervention, any sponsor and status, largest first.

All 10 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • diarrhoea191
  • nausea132
  • constipation111
  • drug ineffective111
  • malignant neoplasm progression98
  • abdominal pain92
  • interstitial lung disease81
  • decreased appetite78
  • malaise69
  • anaemia65
  • pyrexia64
  • vomiting60

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20131
20144
20152
201765
2018371
2019196
2020132
2021134
2022189
2023143
2024156
2025168
2026101

Recalls

1 FDA enforcement reports for this application.

  • Mar 15, 2021 · Class II · Terminated

    CGMP Deviations: Intermittent exposure to temperature excursion during storage.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Symproic (Naldemedine Tosylate)

2024 spending

$9.8M

Beneficiaries

4,141

18,888 claims

Per beneficiary

$2,356

$15.01 per unit

View as table
YearSpending
2020$8,602,455
2021$10,478,630
2022$12,094,634
2023$11,899,468
2024$9,758,066

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 31 on PubMed

Sponsor: Bdsi

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.